Thesis: fraud, analyst: scorpion-capital, sector: pharma.
see below
More ... latest change: 2026-02-28
August 15, 2025 | Investigative report by Scorpion Capital | www.scorpioncapital.com
SOLENO THERAPEUTICS (NASDAQ: SLNO) Russian Roulette With Prader-Willi Children: How The Latest RareDisease Price-Gouging Scheme Fleeced the FDA, Parents, And Its Own Study Investigators With A Worthless, Toxic Drug; Suspect Data; And Sham Clinical Trials To Push A $500K/Year Knockoff Of A 50-Year-Old Generic Compound – Triggering One Of The Worst Launch Failures And Safety Catastrophes In Post-Approval History • The rapid pile-up of reports of children hospitalized for potential heart failure in recent weeks, shortly after starting VYKAT XR, leads us to conclude the drug may be at risk of being withdrawn from market; or that new prescriptions may plunge. • SLNO is a replay of the Zafgen (ZFGN) debacle, the last Prader-Willi high-flier stock, which went extinct after two fatalities during its trial circa 2015 - the current fiasco appears to be unfolding at a more devastating pace. • SLNO is at high risk of fading back into obscurity as a zombie biotech that trades near cash - $9/share - round-tripping back to single-digit or penny stock status, as it was a mere ~2.5 years ago when it hit 90 cents. • SLNO is a one-trick pony with no meaningful assets, pipeline or scientific program, and its only drug is an inferior tablet version of a half-century-old suspension, with its core patent expiring in 2026, placing it at risk of demise if VYKAT XR bombs. • SLNO’s launch metrics are hocus-pocus, obscuring its high dependence on a controversial physician in Gainesville, FL – the lead investigator/author on key trials/papers - whom we suspect to be the invisible hand fueling initial start forms. • The investigator has a history of association with failed PWS treatments, such as ZFGN’s (principal investigator); and partnered with an Australian microcap stock promotion peddling a psychedelic for PWS, where the FDA halted its P2 trial. • Key SLNO papers she has co-authored exhibit irregularities consistent with red flags for data integrity and adherence to scientific standards, casting doubt on the validity of SLNO’s trials, publications, and FDA submissions. We intend to shortly submit an emergency Citizen Petition asking the FDA to request Soleno to conduct a voluntary recall of VYKAT XR from the market. If you are a parent or physician aware of serious adverse events which we can include as supplementary evidence, please email contact@scorpioncapital.com or anonymously via the contact form on our site.
Last updated: 2026-03-07 by automated standardization process